Securities Fraud Class Action Against Zynex, Inc. f/k/a Zynex Medical Holdings, Inc.

NEW YORK, May 22, 2009 LawFuel.com – Legal Newswire — The Rosen Law Firm reminds current and former shareholders of Zynex, Inc. (OTCBB:ZYXI) formerly known as Zynex Medical Holdings, Inc. (collectively “Zynex” or the “Company) securities that they have only 17 more days until the June 8, 2009 deadline to move for appointment as lead plaintiff.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS
CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE.
YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER. YOU MAY ALSO RETAIN COUNSEL
OF YOUR CHOICE.

If you purchased Zynex securities between May 21, 2008 and March 31,
2009, inclusive, and wish to join the Zynex class action, or for
further information please call Laurence Rosen, Esq. or Phillip Kim,
Esq. toll-free at 866-767-3653 or email lrosen@rosenlegal.com or
pkim@rosenlegal.com for information on the class action.

You can join the class action online at http://www.rosenlegal.com.

The Complaint charges Zynex, its CEO Sandgaard, and CFO Allison (the
“Defendants”) with violations of the federal securities laws in
connection with Zynex’s issuance of materially false financial
statements to the investing public during the Class Period. On April 1,
2009 Zynex announced that its unaudited financial statements and press
releases issued on results for the first three quarters of 2008 can no
longer be relied upon and the Company would have to issue restated
financial results to reflect adjustments to accounts receivable and net
revenue for such periods. The Company announced that it believes the
cumulative impact of these adjustments will be $5.1 million. This
adverse news caused Zynex’s stock price to fall dramatically, injuring
Zynex shareholders.

The Rosen Law Firm represents investors throughout the United States,
concentrating its practice in securities class actions and shareholder
derivative litigation.

Attorney advertising. Prior results do not guarantee a similar outcome.

Scroll to Top